Skip to main content
. 2020 Dec 1;25(2):801–812. doi: 10.1111/jcmm.16134

FIGURE 3.

FIGURE 3

Gracillin inhibits the STAT3 signalling pathway in human CRC cells. A, Molecular docking of gracillin to the STAT3 binding spots. B, HCT116 cells were transfected with luciferase reporter gene plasmid and treated with gracillin for 12 h. The results were normalized to the Renilla luciferase activity. **P < .01; ****P < .0001. C, HCT116, RKO and SW480 cells were treated with different concentrations of gracillin (0, 2.5, 5.0 or 10.0 μmol/L) for 12 h. Expression levels of P‐STAT3, STAT3, Mcl‐1, GAPDH, VEGF and Survivin were evaluated by the Western blot assays. D, HCT116, RKO and SW480 cells were treated with different concentrations of gracillin (0, 2.5, 5.0 or 10.0 μmol/L) for 12 h. Expression levels of P‐STAT3, STAT3, P‐STAT1, STAT1, P‐STAT4, STAT4 and P‐STAT5, STAT5 and GAPDH were evaluated by the Western blot assays. E, HCT116 cells were transfected with si‐NC or si‐STAT3 (si#1, si#2 or si#3) for 24 h. Expression levels of P‐STAT3, STAT3 and GAPDH were detected by the Western blot assay. F, HCT116 cells were transfected with si‐NC or si‐STAT3 (si#3) for 24 h and then treated with gracillin at different concentrations (0, 1.0, 2.5 or 5.0 μmol/L) for 48 h. Cell proliferation was evaluated by the MTT assay (***P < .001, ****P < .0001)